11/21
03:09 am
hrtx
Heron Therapeutics, Inc. (NASDAQ: HRTX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Medium
Report
Heron Therapeutics, Inc. (NASDAQ: HRTX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/14
12:01 am
hrtx
Heron Therapeutics, Inc. (NASDAQ: HRTX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Heron Therapeutics, Inc. (NASDAQ: HRTX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/13
08:06 am
hrtx
Heron Therapeutics, Inc. (NASDAQ: HRTX) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.
Medium
Report
Heron Therapeutics, Inc. (NASDAQ: HRTX) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.
11/13
02:12 am
hrtx
Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ... [Yahoo! Finance]
Medium
Report
Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ... [Yahoo! Finance]
11/12
11:56 am
hrtx
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
Medium
Report
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]
11/12
08:12 am
hrtx
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance [Yahoo! Finance]
High
Report
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance [Yahoo! Finance]
11/12
07:55 am
hrtx
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
High
Report
Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
11/10
05:37 pm
hrtx
Heron Therapeutics Q3 2024 Earnings Preview Nov. 10, 2024 5:35 PM ET By: Pranav Ghumatkar , SA News Editor [Seeking Alpha]
Medium
Report
Heron Therapeutics Q3 2024 Earnings Preview Nov. 10, 2024 5:35 PM ET By: Pranav Ghumatkar , SA News Editor [Seeking Alpha]
11/7
10:32 am
hrtx
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics [Yahoo! Finance]
Low
Report
Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics [Yahoo! Finance]
11/5
01:33 pm
hrtx
Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock [Yahoo! Finance]
Low
Report
Positive Signs As Multiple Insiders Buy Heron Therapeutics Stock [Yahoo! Finance]
11/4
05:00 pm
hrtx
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
Low
Report
Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
10/29
04:05 pm
hrtx
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
Low
Report
Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
10/10
04:08 pm
hrtx
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
Low
Report
Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
9/25
02:04 pm
hrtx
Heron Therapeutics, Inc. (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Low
Report
Heron Therapeutics, Inc. (NASDAQ: HRTX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
9/25
08:00 am
hrtx
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
Medium
Report
Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
9/11
08:23 am
hrtx
Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors [Seeking Alpha]
Low
Report
Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors [Seeking Alpha]
9/3
08:00 am
hrtx
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
High
Report
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer